The FDA issued draft guidelines aimed at encouraging development of non-opioid therapies for chronic pain, outlining expectations for clinical trial design and broad indications covering multiple pain conditions. It highlights challenges in analgesic research given individual variability in pain experience, but signals regulatory openness to expedited pathways that could accelerate approval for promising compounds. The agency hopes to promote alternatives that reduce opioid reliance while addressing the unmet needs in pain management.